Suppr超能文献

非酒精性脂肪性肝病、糖尿病、肥胖症和肝细胞癌。

Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.

作者信息

Noureddin Mazen, Rinella Mary E

机构信息

Division of Gastrointestinal and Liver Diseases, USC Keck School of Medicine, 2011 Zonal Avenue, HMR 101, Los Angeles, CA 90033, USA.

Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Arkes Pavillion 14-005, Chicago, IL 60611, USA.

出版信息

Clin Liver Dis. 2015 May;19(2):361-79. doi: 10.1016/j.cld.2015.01.012. Epub 2015 Mar 12.

Abstract

Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC). NAFLD is the commonest cause of chronic liver disease. HCC can develop in NAFLD patients even without cirrhosis, suggesting an association between the metabolic process and HCC and raising a concern that many cancers could be missed given high NAFLD prevalence and screening limitations. The increasing prevalence of these conditions and lack of effective treatments necessitate a better understanding of their connection. This article defines the known interrelationships and common pathways between NAFLD, diabetes, obesity and HCC and possible chemoprevention strategies.

摘要

糖尿病和肥胖与非酒精性脂肪性肝病(NAFLD)以及肝细胞癌(HCC)发病率增加相关。NAFLD是慢性肝病最常见的病因。即使没有肝硬化,NAFLD患者也可能发生HCC,这表明代谢过程与HCC之间存在关联,并引发了一种担忧,即鉴于NAFLD的高患病率和筛查局限性,许多癌症可能会被漏诊。这些疾病的患病率不断上升且缺乏有效的治疗方法,因此有必要更好地了解它们之间的联系。本文阐述了NAFLD、糖尿病、肥胖和HCC之间已知的相互关系和共同途径,以及可能的化学预防策略。

相似文献

1
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Clin Liver Dis. 2015 May;19(2):361-79. doi: 10.1016/j.cld.2015.01.012. Epub 2015 Mar 12.
2
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
3
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
5
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.
6
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29.
9
[Prevalence and harm of nonalcoholic fatty liver disease].
Zhonghua Gan Zang Bing Za Zhi. 2019 Jan 20;27(1):10-13. doi: 10.3760/cma.j.issn.1007-3418.2019.01.004.
10
The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
Liver Int. 2016 Mar;36(3):317-24. doi: 10.1111/liv.13031. Epub 2015 Dec 25.

引用本文的文献

2
Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.
Front Oncol. 2025 Apr 8;15:1526206. doi: 10.3389/fonc.2025.1526206. eCollection 2025.
3
Clinical Characteristics of Non-B and Non-C Biopsy-Proven Primary Liver Cancers in an HBV- Endemic Area: A Retrospective Study.
J Hepatocell Carcinoma. 2024 Apr 24;11:767-774. doi: 10.2147/JHC.S455741. eCollection 2024.
4
Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer.
Methods Mol Biol. 2024;2769:189-198. doi: 10.1007/978-1-0716-3694-7_14.
5
Microfluidic 3D hepatic cultures integrated with a droplet-based bioanalysis unit.
Biosens Bioelectron. 2024 Mar 15;248:115896. doi: 10.1016/j.bios.2023.115896. Epub 2023 Nov 30.
10
Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD - An Umbrella Overview of Systematic Review of Meta-Analysis.
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):656-665. doi: 10.1016/j.jceh.2022.11.006. Epub 2022 Nov 19.

本文引用的文献

1
Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.
Clin Gastroenterol Hepatol. 2015 Mar;13(3):594-601.e1. doi: 10.1016/j.cgh.2014.08.013. Epub 2014 Aug 19.
2
Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden.
Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1101-6. doi: 10.1002/pds.3685. Epub 2014 Jul 29.
3
Controversies in the Diagnosis and Management of NAFLD and NASH.
Gastroenterol Hepatol (N Y). 2014 Apr;10(4):219-27.
4
Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.
PLoS One. 2014 May 15;9(5):e95485. doi: 10.1371/journal.pone.0095485. eCollection 2014.
6
The paradox of the unfolded protein response in cancer.
Anticancer Res. 2013 Nov;33(11):4683-94.
7
The unfolded protein response in fatty liver disease.
Semin Liver Dis. 2013 Nov;33(4):321-9. doi: 10.1055/s-0033-1358522. Epub 2013 Nov 12.
8
NAFLD, NASH and liver cancer.
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. doi: 10.1038/nrgastro.2013.183. Epub 2013 Oct 1.
9
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States.
Am J Gastroenterol. 2013 Aug;108(8):1314-21. doi: 10.1038/ajg.2013.160. Epub 2013 Jun 11.
10
The mTOR pathway in hepatic malignancies.
Hepatology. 2013 Aug;58(2):810-8. doi: 10.1002/hep.26323. Epub 2013 Apr 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验